

Exploring Ethicon's haemostat portfolio¹⁻⁴



Continuous Oozing



SURGICEL® Powder




Difficult to access



**SURGIFLO®
with Thrombin**



Potential rebleeding risk



**EVICEL® Solutions for
Fibrin Sealant Fibrinogen,
Thrombin (Human)**

SURGICEL® Family of Absorbable Haemostats

- Bactericidal against top 5 pathogens: MRSA, VRE, E. coli, PRSP, MRSE¹
- Fully absorbed by the body in 7-14 days²
- Dual level interaction - vasoconstriction and platelet plug formation³
- SURGICEL® Powder provides 52% faster time to haemostasis than SURGICEL® Original^{4*}



* Preclinical study

1.SURGICEL® Technical Report. 2018. 2. Hutchinson RW *et al.* 2013. 3 Vyas KS *et al.* 2013 4. Ethicon SURGICEL® Powder vs SURGICEL® Original Report 2015

SURGIFLO® with Thrombin

- *Flowable gelatin that absorbs completely in 4-6 weeks¹*
- *Achieves haemostasis within 2 minutes when mixed with Thrombin^{*2}*
- *Uniform consistency over 8 hours³*
- *Faster preparation time versus competitor products⁺⁴*



^{*}Thrombin reconstitution was 13 seconds for SURGIFLO® vs 136 seconds for FLOSEAL 10ml kit^{*2}

⁺Compared to 10 mL FLOSEL Hemostatic Matrix⁴

EVICEL® Solutions for Fibrin Sealant Fibrinogen, Thrombin (Human)

Results from a Cochrane review suggest that fibrin sealants are efficacious in reducing both post-operative blood loss and peri-operative exposure to allogeneic RBC transfusion¹

- *Evicel may be effective in reducing red blood cells and plasma transfusion as well as hospital stay²*
- *Sustained haemostasis, even in high-risk patients^{3,4}*
- *Airless spray technology eliminates the need for external gas sources and reduces setup time⁵*
- *Ready when you need it. Storage up to 2 years in freezer, 30 days in refrigerator⁶*



EVICEL[®] Product Information

PBS Information: This product is not listed on the PBS

PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING
(available from Johnson & Johnson Medical Pty Ltd 1–5 Khartoum Rd, North Ryde NSW 2113 Australia).

EVICEL[®] Solutions for fibrin sealant. Fibrinogen, thrombin (human) MINIMUM PRODUCT INFORMATION Fibrinogen Solution: 1mL contains Fibrinogen 80-120mg/mL total protein (clottable protein (human) 50-90mg); and Thrombin Solution: 1mL contains 800 to 1,200 IU Thrombin (human). **INDICATIONS** Supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. As suture support for haemostasis in large vessel vascular surgery. For suture line sealing in dura mater closure. **DOSAGE AND ADMINISTRATION** Before use, the product must reach 20-30°C. The volume and frequency is dependent on the clinical needs of the patient. The initial volume should be sufficient to entirely cover the intended application area. The application can be repeated, if necessary. EVICEL[®] is for episessional use only. Before application, the surface of the wound should be as dry as possible. See full PI. **CONTRAINDICATIONS** Hypersensitivity to the actives or excipients. Injection into tissues is contraindicated. EVICEL[®] should only be applied topically. Soft tissue injection of EVICEL[®] carries the risk of an anaphylactic reaction and/or local tissue damage and/ or thromboembolic complications. Spray application of EVICEL[®] should not be used in endoscopic procedures. Must not be used for sealing the suture line in dura mater if there are gaps of greater than 2mm after suturing. Must not be used as a glue for the fixation of dural patches. Must not be used as a sealant when the dura mater cannot be sutured. See full PI. **PRECAUTIONS** Viral and Prion Risk: Products made from human plasma may contain infectious agents which can cause disease, such as viruses and theoretically Creutzfeldt-Jakob Disease (CJD) agents. See full PI. **General:** The PI gives guidance on the use of the spray device. Air or gas embolism, tissue rupture, or gas entrapment with compression, which may be life-threatening, have occurred with the use of spray devices. Cover areas outside application to prevent tissue adhesion at undesired sites. EVICEL[®] spray application should only be used if it is possible to accurately judge the spray distance, especially during laparoscopy. Spray distance from tissue and pressure should be within the ranges recommended by the manufacturer. Adequate data are not available to support administration of EVICEL[®] through a flexible endoscope for the treatment of bleeding or in gastrointestinal anastomoses. Not to be used for treatment of massive and brisk arterial or venous bleeding. Avoid injection into the nasal mucosa as severe allergic/anaphylactoid reactions can occur and thromboembolic complications may occur in the area of the ophthalmic artery. The use of EVICEL[®] in patients undergoing radiotherapy within 7 days after surgery, and the use as a sealant in transphenoidal otoneurosurgical procedures and spinal procedures has not been evaluated. Complete haemostasis should be achieved before application of EVICEL[®] to seal the dural suture line. See full PI. **USE IN PREGNANCY** Category B2. See full PI. **ADVERSE EVENTS** Hypersensitivity, allergic reactions, severe anaphylaxis. Antibodies to active components may occur rarely. Intravascular injection could lead to thromboembolic events, disseminated intravascular coagulation (DIC). See full PI. **PRESENTATION** 2mL composite pack containing Fibrinogen Solution 1mL and Thrombin Solution 1mL. 4mL composite pack containing Fibrinogen Solution 2mL and Thrombin Solution 2mL. 10mL composite pack containing Fibrinogen Solution 5mL and Thrombin Solution 5mL. Store in a freezer at or below -18°C. Keep the vials upright in the outer carton protect from light. Do not refreeze. After thawing, unopened vials can be stored at 2-8°C and protected from light for up to 30 days, the components are stable at or below 25°C for up to 24 hours. Date of preparation 11 January 2017. Please review the Product information before prescribing. Evicel is registered in Australia. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02766-1> Manufacturer Omrix Biopharmaceuticals, Ltd. Israel License No. 1603US-2009/10/180 Australian Sponsor Johnson & Johnson Medical Pty Ltd 1-5 Khartoum Road, North Ryde 2113, NSW, Australia AUST R 266221, AUST R 181318, AUST R 181319.

ETHICON
PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

Shaping
the future
of surgery